A Phase 2/3 interventional study of Placebo and sodium nitrite 45 mg in Out-Of-Hospital Cardiac Arrest, sponsored by University of Washington. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-24.
Sponsored by University of Washington · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Out-of-Hospital Cardiac Arrest with a site in United States — 11 open to participants now, 15 under way, 1 of them phase 3. Out-of-Hospital Cardiac Arrest · United States.
Among the 37 studies in Out-of-Hospital Cardiac Arrest with a site in United States, this one is the 8th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2018, is one of 2 in phase 2/3, and was the 17th registered.
314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.
Browse Out-of-Hospital Cardiac Arrest studies →11 of the 37 studies in Out-of-Hospital Cardiac Arrest with a site in United States are open now. Recruiting first, the newest first:
University of Massachusetts, Worcester · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–60
University of Pittsburgh · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
University of Michigan · Sites in United States, Australia, Canada and 2 more countries
Ages 2 days–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 3 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,502 is above the median of 218 across 179 interventional studies indexed under Out-of-Hospital Cardiac Arrest.
Median enrollment 340 across the 27 interventional studies, 637 across the 10 observational. Of the 20 that completed or were terminated, 10 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 37 have an industry lead sponsor. The 10 most frequent:
University of Washington is the lead sponsor of 1,434 studies on the registry; 226 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 136 (86%) have results posted.
University of Washington has 6 studies filed under Out-of-Hospital Cardiac Arrest — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 37 studies in Out-of-Hospital Cardiac Arrest with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this clinical study, a total of 1500 patients with out-of-hospital cardiac arrest in Seattle/King County will be enrolled. This will be a randomized clinical trial and patients will receive either two different doses of IV sodium nitrite (45 mg or 60 mg) or placebo during resuscitation in the field by paramedics. The primary outcome will be proportion of patients surviving to hospital admission.
The hemodynamic effects of the optimal dose of IV nitrite administered in patients with cardiac arrest are unknown. A significant negative hemodynamic effect from nitrite would decrease the proportion of patients admitted to the hospital, increase rate of re-arrest, or increase the need for vasopressor support in the field. In Seattle/King County, typically 40% of out-of-hospital cardiac arrest patients attended to by paramedics have Return of spontaneous circulation (ROSC) and are admitted to the hospital. In this study, 1500 patients with out-of-hospital cardiac arrest who are undergoing resuscitation by paramedics will be randomized to receive placebo (n=500) or 45 mg IV (n=500) or 60 mg dose (n=500) of sodium nitrite. The study will have 80% power to detect an absolute increase in hospital admission rate of 8% (1-sided .05 level test for each of the two comparisons (45 mg vs placebo and 60 mg vs placebo, no adjustment for multiple comparisons), with a hospital admission rate of 40% in the placebo group and with one interim analysis and stopping only for potential futility and/or harm). The investigators will examine the proportion of patients who survive to discharge as a secondary measure of efficacy.
Patients will be eligible for this study if:
Exclusion Criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
2 ml of normal saline (n=500)
Drug: Placebo
45 mg IV of sodium nitrite (n=500) or 60 mg IV sodium nitrite (n=500) given during active resuscitation from out of hospital cardiac arrest.
Drug: sodium nitrite 45 mg · Drug: sodium nitrite 60 mg
500 patients will 2 ml of normal saline
500 patients will receive 45 mg IV sodium nitrite
500 patients will receive a dose of 60 mg IV sodium nitrite
Number of Participants Who Survived to Hospital Admission
Patient has sustained pulse at arrival to the emergency department
Time frame: within 24 hours after out of hospital cardiac arrest
Survival to Discharge
Patient alive at time of discharge from hospital
Time frame: within 3-6 months after cardiac arrest
Number of Days in ICU
Number of days the patient is admitted to the Intensive Care Unit
Time frame: Within first 3 months of hospital admission
Survival to 24 Hours
Patient is alive after the first 24 hours after admission to the hospital
Time frame: within first 24 h after hospital admission
Re-arrest
Patient loses pulses during transport to the hospital. Event occurs before admission to hospital.
Time frame: before hospital arrival
Survival to 48 Hours After Admission to Hospital
Patient is alive after first 48 hours after admission to the hospital
Time frame: within first 48 hours after admission to hospital
Survival to 72 Hours After Admission to Hospital
Patient is alive after first 72 hours after admission to the hospital
Time frame: within first 72 hours after admission to hospital
A total of 1502 were enrolled. A total of 1497 were randomized. 5 patients were excluded due to missing kit information.
| Milestone | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg |
|---|---|---|---|
| Started | 499 | 500 | 498 |
| Completed | 499 | 500 | 498 |
| Not completed | 0 | 0 | 0 |
Patient has sustained pulse at arrival to the emergency department
| Participants | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg |
|---|---|---|---|
| Number of Participants Who Survived to Hospital Admission | 218 | 205 | 212 |
Patient alive at time of discharge from hospital
| Participants | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg |
|---|---|---|---|
| Survival to Discharge | 74 | 66 | 72 |
Number of days the patient is admitted to the Intensive Care Unit
| days | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg |
|---|---|---|---|
| Number of Days in ICU | 6.7 ± 8.1 | 8.9 ± 10.4 | 7.3 ± 7.2 |
Patient is alive after the first 24 hours after admission to the hospital
| Participants | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg |
|---|---|---|---|
| Survival to 24 Hours | 181 | 170 | 171 |
Patient loses pulses during transport to the hospital. Event occurs before admission to hospital.
| Participants | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg |
|---|---|---|---|
| Re-arrest | 139 | 130 | 156 |
Patient is alive after first 48 hours after admission to the hospital
| Participants | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg |
|---|---|---|---|
| Survival to 48 Hours After Admission to Hospital | 161 | 152 | 151 |
Patient is alive after first 72 hours after admission to the hospital
| Participants | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg |
|---|---|---|---|
| Survival to 72 Hours After Admission to Hospital | 142 | 133 | 131 |
Collected over Adverse events were collected from time period of randomization to hospital discharge. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 422/496 (85.1%) | 280/496 (56.5%) | 21/496 (4.2%) |
| Sodium Nitrite 45 mg | 433/499 (86.8%) | 249/499 (49.9%) | 19/499 (3.8%) |
| Sodium Nitrite 60 mg | 425/497 (85.5%) | 268/497 (53.9%) | 15/497 (3%) |
| Event | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg |
|---|---|---|---|
| Pressors in first 24 hours after hospitalizationCardiac disorders | 190/496 | 173/499 | 185/497 |
| Re-arrest first 24 hours of hospitalizationCardiac disorders | 76/496 | 65/499 | 74/497 |
| sustained hypotension in hospital, first 24 hoursCardiac disorders | 14/496 | 11/499 | 9/497 |
| Event | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg |
|---|---|---|---|
| Positive troponinCardiac disorders | 21/496 | 19/499 | 15/497 |
5 patients were excluded since they were incarcerated or were less than 18 years of age. We were not allowed to use their data. There were 1492 patients available for analysis.
| Age, Categorical(Participants) | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg | Total |
|---|---|---|---|---|
| <=18 years | 0 | 1 | 0 | 1 |
| Between 18 and 65 years | 222 | 242 | 254 | 718 |
| >=65 years | 274 | 256 | 243 | 773 |
| Age, Continuous(years) | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg | Total |
|---|---|---|---|---|
| Median | 67 (55 to 76) | 65 (56 to 76) | 64 (52 to 76) | 65 (55 to 76) |
| Sex: Female, Male(Participants) | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg | Total |
|---|---|---|---|---|
| Female | 165 | 170 | 167 | 502 |
| Male | 331 | 329 | 330 | 990 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 12 | 14 | 10 | 36 |
| Not Hispanic or Latino | 186 | 201 | 192 | 579 |
| Unknown or Not Reported | 298 | 284 | 295 | 877 |
| Race/Ethnicity, Customized(Participants) | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg | Total |
|---|---|---|---|---|
| White | 271 | 288 | 273 | 832 |
| Black | 49 | 58 | 51 | 158 |
| Asian | 38 | 39 | 31 | 108 |
| Other | 3 | 5 | 2 | 10 |
| Unknown | 135 | 109 | 140 | 384 |
| Region of Enrollment(participants) | Placebo | Sodium Nitrite 45 mg | Sodium Nitrite 60 mg | Total |
|---|---|---|---|---|
| United States | 496 | 499 | 497 | 1492 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Feb 2018 to primary completion in Dec 2019, 22 months.
Results were first posted in May 2023, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Nitrite
Out-of-Hospital Cardiac Arrest →